Analysts have been eager to weigh in on the Healthcare sector with new ratings on Atossa Genetics (ATOS), Amgen Inc (AMGN) and Emergent Biosolutions (EBS).
Atossa Genetics (ATOS)
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Atossa Genetics, with a price target of $9. The company’s shares closed yesterday at $2.44.
McCarthy wrote:
“Atossa reported 1Q19 with a net loss of ($4.1M). The company ended the period with $19.6M in cash on the balance sheet.”
According to TipRanks.com, McCarthy has currently no stars on a ranking scale of 0-5 stars, with an average return of -13.2% and a 26.5% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, SELLAS Life Sciences Group Inc, and ContraVir Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Atossa Genetics with a $9 average price target.
See today’s analyst top recommended stocks >>
Amgen Inc (AMGN)
Cowen & Co. analyst Yaron Werber maintained a Buy rating on Amgen Inc yesterday and set a price target of $229. The company’s shares closed yesterday at $169.87, close to its 52-week low of $166.30.
According to TipRanks.com, Werber is a 5-star analyst with an average return of 12.9% and a 61.4% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., Rocket Pharmaceuticals Inc, and Unum Therapeutics Inc.
Currently, the analyst consensus on Amgen Inc is a Moderate Buy with an average price target of $212.33, representing a 25.0% upside. In a report issued on April 30, Mizuho Securities also maintained a Buy rating on the stock with a $208 price target.
Emergent Biosolutions (EBS)
Cowen & Co. analyst Boris Peaker maintained a Hold rating on Emergent Biosolutions yesterday and set a price target of $60. The company’s shares closed yesterday at $45.24, close to its 52-week low of $43.35.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 3.3% and a 41.8% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Emergent Biosolutions with a $66.75 average price target, implying a 47.5% upside from current levels. In a report issued on May 9, Wells Fargo also maintained a Hold rating on the stock with a $61 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
